DR. DAI LU, MD
Anesthesiologist Assistant at Citywest Blvd, Houston, TX

License number
Texas K6882
Category
Osteopathic Medicine
Type
Anesthesiology
Address
Address 2
1500 Citywest Blvd STE. 300, Houston, TX 77042
PO Box 650865, Dallas, TX 75265
Phone
(713) 620-4000
(713) 458-4229 (Fax)
(972) 233-1999
(972) 233-3666 (Fax)

Personal information

See more information about DAI LU at radaris.com
Name
Address
Phone
Dai Lu
10314 Indigo Broom Loop, Austin, TX 78733
Dai Lu
1603 Scenic Mountain Ct, Humble, TX 77345
Dai Lu
7900 Cambridge St APT 2-1A, Houston, TX 77054
Dai Lu
Humble, TX
(281) 360-3071

Professional information

See more information about DAI LU at trustoria.com
Dai Lu Photo 1
Bcr-Abl Directed Compositions And Uses For Inhibiting Philadelphia Chromosome Stimulated Cell Growth

Bcr-Abl Directed Compositions And Uses For Inhibiting Philadelphia Chromosome Stimulated Cell Growth

US Patent:
6107457, Aug 22, 2000
Filed:
Feb 16, 1995
Appl. No.:
8/390353
Inventors:
Ralph B. Arlinghaus - Bellaire TX
Jiaxin Liu - Bellaire TX
Dai Lu - Houston TX
Assignee:
Board of Regents, The University of Texas System - Austin TX
International Classification:
C07K 700, C07K 1400
US Classification:
530300
Abstract:
Compositions comprising a mixture of peptides that bind to molecules involved in Bcr-Abl oncoprotein function are disclosed. In addition, expression of functional BCR protein (p160 BCR) or amino terminal fragments thereof (159, 221 and 413 amino terminal residues) by way of retrovirus vectors will oppose the biological function of Bcr-Abl (p160 BCR) or inactivate Bcr-Abl tyrosine kinase function or its signal transduction function. Bcr and Abl peptides, either tyrosine phosphorylated or unphosphorylated, that bind to a region near the amino terminus of Bcr to prevent formation of tetramer Bcr-Abl molecules, that bind to the SH2 domain of Grb2, to sites on tyrosine phosphorylated Shc protein, to sites of Crkl, and to an SH2 domain of Ras Gap comprise particular peptide preparations of the invention. The peptides and polypeptides inhibit Bcr-Abl oncoprotein activation, or block the oncogenic signal generated by the Bcr-Abl oncoprotein and, thereby, inhibit growth and induce cell death of leukemia cells expressing the oncoprotein. Methods for processing bone marrow using the peptide and polypeptide compositions of the invention are also provided.